The International Generic and Biosimilar Medicines Association (IGBA) welcomes the decision of the ICH General Assembly to re-elect the IGBA as a Management Committee Member of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). IGBA joined the ICH as a full member of the General Assembly in June 2016 and was elected to the Management Committee in 2018.
Non-communicable diseases (NCDs) are on the rise and impacting the lives of people around the world. IGBA is pleased to join IFPMA, DITTA, GSCF, WHL, and PATH in a formal statement at WHA on the need for multistakeholder solutions to build a healthier, more sustainable future for all.
Chief Executive Officers of the world’s largest generic and biosimilar medicines companies met in Vienna on 15 May 2024 to provide strategic advice to the International Generic and Biosimilar Medicines Association (IGBA). The generics and biosimilars sector, which supplies 70 to 90% of prescribed medicines around the world, is united in seeking to enable innovation and competition to improve patients’ access to quality-assured, safe and cost-effective medicines.
